Utilizad este identificador para citar o enlazar este documento: http://hdl.handle.net/2072/227796

Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis.
Cruz, N.; Sanchez-Moreno, J.; Torres, F.; Goikolea Alberdi, José Manuel; Valentí Ribas, Marc, M.; Vieta i Pascual, Eduard, 1963-
Randomized, controlled trials have demonstrated efficacy for second-generation antipsychotics in the treatment of acute mania in bipolar disorder. Despite depression being considered the hallmark of bipolar disorder, there are no published systematic reviews or meta-analyses to evaluate the efficacy of modern atypical antipsychotics in bipolar depression. We systematically reviewed published or registered randomized, double-blind, placebo-controlled trials (RCTs) of modern antipsychotics in adult bipolar I and/or II depressive patients (DSM-IV criteria). Efficacy outcomes were assessed based on changes in the Montgomery-Asberg Depression Rating Scale (MADRS) during an 8-wk period. Data were combined through meta-analysis using risk ratio as an effect size with a 95% confidence interval (95% CI) and with a level of statistical significance of 5% (p<0.05). We identified five RCTs; four involved antipsychotic monotherapy and one addressed both monotherapy and combination with an antidepressant. The two quetiapine trials analysed the safety and efficacy of two doses: 300 and 600 mg/d. The only olanzapine trial assessed olanzapine monotherapy within a range of 5-20 mg/d and olanzapine-fluoxetine combination within a range of 5-20 mg/d and 6-12 mg/d, respectively. The two aripiprazole placebo-controlled trials assessed doses of 5-30 mg/d. Quetiapine and olanzapine trials (3/5, 60%) demonstrated superiority over placebo (p<0.001). Only 2/5 (40%) (both aripiprazole trials) failed in the primary efficacy measure after the first 6 wk. Some modern antipsychotics (quetiapine and olanzapine) have demonstrated efficacy in bipolar depressive patients from week 1 onwards. Rapid onset of action seems to be a common feature of atypical antipsychotics in bipolar depression. Comment in The following popper user interface control may not be accessible. Tab to the next button to revert the control to an accessible version.Destroy user interface controlEfficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis--results to be interpreted with caution.
Trastorn bipolar
Assaigs clínics de medicaments
Manic-depressive illness
Antipsychotic drugs
Drug testing
Placebos (Medicine)
(c) CINP (Collegium Internationale Neuro-Psychopharmacologicum) , 2010
Cambridge University Press

Mostrar el registro completo del ítem

Documentos relacionados

Otros documentos del mismo autor/a

Madre, M.; Pomarol-Clotet, E.; McKenna, P.; Radua, J.; Ortiz Gil, Jordi; Panicali, F.; Goikolea Alberdi, José Manuel; Vieta i Pascual, Eduard, 1963-; Sarró, S.; Salvador, R.; Amann, B. L.
Salazar-Fraile, J.; Balanza-Martinez, V.; Selva-Vera, G.; Martínez-Arán, Anabel, 1971-; Sanchez-Moreno, J.; Rubio, C.; Vieta i Pascual, Eduard, 1963-; Gomez-Beneyto, M.; Tabares-Seisdedos, Rafael
Hernández Ferràs, Joan Manel; Torres, F.; Tejada Palacios, Javier; Molins i Grau, Elies
Vieta i Pascual, Eduard, 1963-; Benabarre Hernández, Antonio; Colom, F.; Gastó Ferrer, Cristóbal; Nieto, E.; Otero, A.; Vallejo Ruiloba, Julio